Drugs / HB-502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06430905 | Jul 2024 → Jul 2025 | HIV infectious disease | Hookipa Biotech GmbH | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06430905 ↗ |
| Route | Intramuscular | “administered intramuscularly every 8 weeks” NCT06430905 ↗ |